Michael F MacLean
CIK 1383731 · Chief Financial Officer · last filed 2026-04-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.91M
Companies
6
Total Filings
59
Lifetime Open-Market Net
-$16.65M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | — | $3.42 | — | $0 | 1 | 2026-04-03 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Chief Financial Officer | 0 | — | — | $0 | 1 | 2026-02-27 |
| RNA | Chief Financial Officer | 62,025 | $11.49 | $712.7K | -$15.13M | 18 | 2026-01-23 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 7 | 2025-07-28 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Chief Financial Officer | 48,000 | — | — | $0 | 6 | 2020-01-16 |
| BIIB | SVP, Chief Accounting Officer | 10,681 | $205.61 | $2.20M | -$1.52M | 21 | 2010-10-04 |
Recent Filings · Page 3 of 6
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-14 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −75,000 | -$1.95M | EDGAR |
| 2024-03-15 | RNA | Mixed | — | -$628.0K | EDGAR |
| 2024-03-13 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −40,000 | -$907.6K | EDGAR |
| 2024-01-23 | RNA | Mixed | +20,884 | -$16.4K | EDGAR |
| 2023-09-12 | RNA | Grant (A) | — | $0 | EDGAR |
| 2023-06-20 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-02-16 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-24 | RNA | Grant (A) | +18,500 | $0 | EDGAR |
| 2022-06-13 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-15 | RNA | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.